Cinctive Capital Management LP Makes New $6.69 Million Investment in Insulet Corporation $PODD

Cinctive Capital Management LP purchased a new position in shares of Insulet Corporation (NASDAQ:PODD) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 21,660 shares of the medical instruments supplier’s stock, valued at approximately $6,687,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PODD. True Wealth Design LLC grew its stake in Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares during the last quarter. Whittier Trust Co. of Nevada Inc. increased its position in Insulet by 48.9% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 43 shares in the last quarter. Quent Capital LLC purchased a new stake in Insulet in the third quarter valued at about $49,000. Osterweis Capital Management Inc. purchased a new stake in Insulet in the second quarter valued at about $51,000. Finally, Zions Bancorporation National Association UT boosted its holdings in Insulet by 57.3% in the third quarter. Zions Bancorporation National Association UT now owns 173 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 63 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on PODD shares. Citigroup dropped their price target on Insulet from $345.00 to $338.00 and set a “buy” rating on the stock in a research note on Wednesday. Zacks Research cut shares of Insulet from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a research report on Thursday, January 22nd. The Goldman Sachs Group cut their price target on shares of Insulet from $363.00 to $326.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Finally, Evercore set a $340.00 price target on shares of Insulet in a report on Thursday, February 19th. Twenty investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $354.24.

Insider Buying and Selling at Insulet

In other Insulet news, Director Michael R. Minogue purchased 2,030 shares of Insulet stock in a transaction that occurred on Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the acquisition, the director owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.39% of the stock is currently owned by corporate insiders.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Study results support long‑term product thesis: new study outcomes backing a fully closed‑loop insulin pump for type 2 diabetes could reinforce Insulet’s growth runway if commercial adoption follows. Study Outcomes
• Neutral Sentiment: Company says affected supply is limited and replacement capacity exists — Insulet initiated a voluntary medical device correction and communicated it publicly, and management stated they expect to replace impacted Pods without disrupting overall availability. Investors should watch follow‑up disclosures for replacement costs and execution risk. Company Correction
• Negative Sentiment: Recall / Medical device correction highlights manufacturing defect — Regulators and media report specific U.S. lots of Omnipod 5 Pods were recalled/subject to correction because of potential tubing tears that could under‑deliver insulin, increasing short‑term revenue and reputation risk. Reuters Recall
• Negative Sentiment: Safety reports and potential patient harm amplified selling — Insulet disclosed multiple serious adverse event reports (including hospitalizations and DKA tied to under‑delivery) which raises regulatory/legal exposure and hurts investor confidence. Seeking Alpha Recall
• Negative Sentiment: Multiple securities‑fraud investigations and law‑firm notices have been announced — several firms are soliciting claimants alleging the company may have misled investors about the issue, creating potential litigation risk and additional headline pressure. Fraud Investigation
• Negative Sentiment: Market coverage and technicals: the headlines drove the stock to a 52‑week low and broader market writeups (MSN/Benzinga) are amplifying downward momentum. Expect short‑term analyst and sentiment reactions until clarity on scope, costs and regulatory response. 52‑Week Low

Insulet Stock Down 6.9%

PODD stock opened at $219.84 on Friday. The firm has a market cap of $15.48 billion, a PE ratio of 62.81, a P/E/G ratio of 1.31 and a beta of 1.42. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The firm’s fifty day moving average is $258.47 and its 200 day moving average is $297.07. Insulet Corporation has a one year low of $216.49 and a one year high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The business had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. During the same quarter in the prior year, the firm posted $1.15 earnings per share. The company’s revenue was up 31.2% compared to the same quarter last year. On average, research analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.